ALR Technologies Announces Strategic Acquisition of CGM Medical Technology for US$45 Million & 200M Shares

ALR Technologies SG Ltd ("ALRT") has announced its intention to acquire CGM Medical Technology Singapore Pte. Ltd. and the assets of CGM Medical Technology Shenzhen Ltd for a total deal value of $45 million, alongside the issuance of 200 million ordinary shares. This acquisition, formalized through a Letter of Intent, is aimed at enhancing ALRT's capabilities in the diabetes management sector. The transaction is expected to close subject to various conditions, including regulatory approvals, with a definitive agreement anticipated by July 31, 2026.

ALRT, a company focused on diabetes management solutions, aims to become a fully integrated provider in the diabetes care market through this acquisition. The inclusion of CGM Medical Singapore and its Shenzhen counterpart will allow ALRT to gain control over the intellectual property and technology necessary for producing continuous glucose monitoring (CGM) devices. This strategic move follows the successful launch of the GluCurve Pet CGM, a specialized monitoring system for diabetic pets, which highlights ALRT's commitment to expanding its product offerings in both human and veterinary health.

CGM Medical Technology Singapore is recognized for its expertise in biomedical engineering and technology transfer, which will be instrumental in developing and commercializing additional medical devices for diabetes management and other chronic diseases. The acquisition will provide ALRT with the necessary resources to build a state-of-the-art manufacturing facility in the Johor-Singapore Special Economic Zone, aimed at producing up to 500,000 CGMs per month. This facility is expected to significantly enhance ALRT's production capabilities and operational margins.

The deal also includes a structured payment plan for the acquisition of CGM Medical Shenzhen, which is contingent upon achieving specific production milestones. ALRT will initially pay $1 million, with further payments tied to 25% of the free cash flow generated by the company until the total amount owed is settled. This approach not only aligns the interests of both parties but also mitigates financial risk for ALRT as it scales its operations.

The broader implications of this acquisition reflect a growing trend in the medical devices sector, where companies are increasingly seeking vertical integration to enhance product offerings and streamline operations. As diabetes prevalence continues to rise globally, the demand for innovative and efficient monitoring solutions is expected to increase, positioning ALRT favorably within this expanding market. The successful completion of this acquisition could set a precedent for similar transactions in the healthcare sector, as companies strive to consolidate resources and capabilities to meet evolving consumer needs.